⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27273552 | 0.78 | TSHR (0.34) | — | |
| SCHEMBL132218 | 0.77 | — | — | |
| SCHEMBL4097413 | 0.75 | — | — | |
| SCHEMBL130846 | 0.75 | — | — | |
| SCHEMBL12000 | 0.75 | — | — | |
| SCHEMBL10966725 | 0.73 | — | — | |
| SCHEMBL6637707 | 0.73 | TAAR1 (0.34) | — | |
| SCHEMBL3465792 | 0.73 | TAAR1 (0.34) | — | |
| SCHEMBL2126059 | 0.72 | — | — | |
| SCHEMBL7384491 | 0.72 | DAO (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627631-B1 | PYRROLIDINONES AS METAP2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-12-16 | — | — | EP | claimed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4050005-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-2710018-B1 | MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2018-10-25 | — | — | US | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| CN-1022754-C | Novel aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds preparation method | MERRELL DOW PHARMA (US) | 1993-11-17 | — | — | CN | disclosed |
| US-5051429-A | For treatment of autoimmune diseases such as arthritis, lupus, antiinflammatory agents, multiple sclerosis, diabetes and viral diseases | WARNER-LAMBERT CO. (US) | 1991-09-24 | — | — | US | disclosed |
| US-5041554-A | Replace steroids in treatment of inflammatory diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| US-5039695-A | Method of using aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds in the treatment of interleukin-1 mediated conditions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4952693-A | TREATING AUTOIMMUNE DISEASES | WARNER-LAMBERT COMPANY (US) | 1990-08-28 | — | — | US | disclosed |
| CN-1044653-A | The new aryl or the heteroaryl-I-alkyl-pyrroles-2-carboxylic acid that are used for the treatment of the pathological state of interleukin-I mediation | MERRELL DOW PHARMA (US) | 1990-08-15 | — | — | CN | disclosed |
| EP-0381141-A2 | Novel aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions | MERRELL PHARMACEUTICALS INC. (US) | 1990-08-08 | — | — | EP | disclosed |
| EP-0381142-A2 | Method of using aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds in the treatment of interleukin-1 mediated conditions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-08 | — | — | EP | disclosed |
| US-4772606-A | AUTOIMMUNE DISEASES, ORGAN TRANSPLANTS | WARNER-LAMBERT COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0178178-A2 | Purine derivatives | WARNER-LAMBERT COMPANY (US) | 1986-04-16 | — | — | EP | disclosed |